Connect with us

News

CBD guides: Five things every athlete should know about CBD

Athletes may be curious about starting CBD but unsure if it will interfere with their sport or cause them to fail a drugs test

Published

on

Athletes put a lot of stress and strain on their body while training. If you are curious about trying CBD, here are five answers to some of the most common questions.

What is CBD

CBD is just one of many cannabinoids that exist naturally in the cannabis plant. It is non-psycoactive which means it won’t get you high but it is thought to have many benefits for athletes especially when it comes to post-training pain.

Its available in many different forms from oils and vapes to creams or edibles. Choosing the right CBD for you depends on personal preference, lifestyle and what you are trying to treat.

Athlete: A banner advert for IMPACT CBD showing a bottle of CBD oil and a torso of a woman

Is CBD a banned substance in sport?

The World Anti-Doping Agency (WADA) removed CBD from their list of prohibited substances. The US Anti-Doping Agency (USADA) also removed CBD.

It is worth noting that THC is still a banned substance as well as synthetic cannabinoids that have simular effects. The ban on THC is what led to Sha’ Carri Richardson being forced to miss the Tokyo Olympics after testing positive. WADA is set to review the ban this year although it will remain in place for at least 2022.

There should be very low quantities of THC in legal CBD products. If in doubt, athletes should check the professional body for the sport that they take part in.

What benefits does CBD have for athletes?

Athletes put a lot of stress and strain on the body during training and competitions. CBD may help with inflammation, pain and relaxation.

READ MORE  Exercise-induced endocannabinoids reduce anxiety, says study

Sore muscles are also referred to as delayed onset muscle soreness (DOMS). The soreness can happen if you change your routine or start a new exercise programme.

This causes microscopic damage to muscle fibres. It can last up to three to five days after your workout which can be alarming for beginners or some athletes. CBD may help by soothing muscle pain and reducing the inflammation around the damage.

A study on CBD and joint pain found that daily doses may help to reduce the pain. The study focused on rats with arthritis and the CBD treatment was applied as a gel.

Athletes: A row of test tubes containing CBGA oil with a doctors white gloved hand holding one up to the light

What’s the best way for athletes to take CBD?

Topicals such as creams, lotions or gels are a great way to target the exact area of pain. The CBD is absorbed through the skin so it can be faster acting than edibles such as protein bars or drinks.

There are also massage oils that can be incorporated into sports massages that contain high levels of CBD. If lotions or potions aren’t your thing, then patches can be another way to get a dose of CBD. They can be applied directly to the painful area and it is absorbed the same way. However, patches do not leave an oily residue which some creams, lotions or gels may which makes it a better way for athletes to use CBD during training.

Will I fail a drugs test?

No.

When an athlete is testing for drugs, they are not looking for CBD. They are testing for the presence of tetrahydrocannabinol (THC) in the blood. This is another cannabinoid and it’s responsible for the high feeling people associate with cannabis.

READ MORE  Five professional athletes who use CBD

If CBD is purchased legally and has lab tests to prove its contents then you should be fine. CBD by law must have below 0.02 per cent THC in order to be sold in the UK. This is an extremely low level of THC which should not be responsible for failing a drugs test.

Some states in the US have legalised THC so it is possible to buy products with THC in them. Some professional sports organisations have announced they are no longer drug testing athletes such as the NBA.

It’s worth knowing the law in your country, and in your state, regarding THC and CBD as well as researching what your sporting organisation allows.

News

New studies examine effects of THC and CBD on stroke

New data suggests both positive and negative effects of cannabis in stroke patients

Published

on

A new study has shown that pre-treatment CBD may have a neuroprotective effect in stroke patients.

The study aimed to investigate the effect of CBD on oxidative stress and cell death which occurs in ischemic stroke patients.

It revealed that the cannabinoid may reduce the destructive effects of cell damage associated with stroke.

Ischemic strokes are the most common type of stroke. They occur when a blood clot blocks a flow of oxygen or blood to the brain. This takes place in arteries that have been narrowed or blocked over time by fatty deposits (plaques). The most common symptoms of a stroke include facial drooping on one side, not being able to lift your arms and slurred speech.

If this occurs, it is vital that a person be taken to the emergency room immediately.

The National Institute of Health Care and Excellence (NICE) estimate that there are around 100,000 strokes every year in the UK. It is also thought that 1.3 million people live with the effects of a stroke.

Stroke recovery and CBD results

The Study showed that CBD reduced the amount of infarction in those samples which had been given the cannabinoid. Infarction refers to the death of tissue as a result of a lack of blood supply and is commonly due to a blood vessel being obstructed or narrowed.

There were also differences in malondialdehyde level (MDA) – a common marker of oxidative stress – between the brains of the CBD group and the vehicle group.

It also revealed that CBD may help to protect tissue by preventing further damage.

READ MORE  How CBD got me back in the game

THC and stroke risk

Another recent study examined the effect that tetrahydrocannabinol (THC) could have on strokes. It found that it may increase the risk of a certain type of stroke among cannabis consumers.

According to findings, cannabis consumers who experience a stroke known as an aneurysmal subarachnoid haemorrhage (aSAH), are twice as likely to develop further complications.

An aSAH occurs when a weakened blood vessel bursts on the surface of the brain leading to bleeding between the brain and tissue that covers it. It can result in neurological disabilities, long-term slurred speech or even death. It is estimated that aSAH affects around eight people per 100,000 of the population each year, accounting for six per cent of first strokes.

The study by the American Stroke Association suggested there is twice the risk of developing delayed cerebral ischemia for cannabis consumers. The researchers analysed data from 1,000 patients who had received treatment for bleeding over a 12 year period. In the group of participants, 36 per cent developed cerebral ischemia and 50 per cent had moderate to severe disabilities.

When comparing the results of patients who tested positive for THC with those who did not, they found cannabis consumers were 2.7 times more likely to develop cerebral ischemia. They were also 2.8 times more likely to develop long-term moderate to severe physical disabilities.

However, compared to those who tested negative for THC, the cannabis group did not have larger aneurysms, higher blood pressures or worse stroke symptoms when admitted to the hospital. They did not have any higher cardiovascular risk factors than the negative group.

READ MORE  The high impact athletes turning to CBD

Researchers are now conducting further studies in which they hope to better understand if THC can impact aneurysm formation and rupture.

Stroke: A banner advert for cannabis health news sign ups

Continue Reading

News

New study shows CBD may prevent Covid-19 infection

Researchers are calling for more trials to determine if CBD could be a preventative or early treatment for the virus.

Published

on

Covid: A covid infection

Researchers are recommending clinical trials to examine if CBD could help to prevent Covid infection after more positive findings have been published.

Researchers from the University of Chicago have reported that CBD may stop the infection of Covid-19 by blocking its ability to replicate in the lungs.

A number of cannabinoids including CBD and THC were tested along with 7-Hydroxycannabidiol (7-OH-CBD) which is thought to be produced when cannabidiol is processed by the body.

The study found that CBD showed a significant negative association with SARS-CoV-2 positive tests in a national sample of patients who were taking  high doses of CBD, prescribed for epilepsy.

As a result of their findings, researchers are calling for more clinical trials to determine whether CBD could eventually be used as a preventative or early treatment for the virus.

Covid- Covid infection

Covid and CBD study

Researchers treated human lung cells with a non-toxic dose of CBD for two hours before exposing the cells to SARS-CoV-2 and monitoring them for the virus and the viral spike protein.

They found that, above a certain threshold concentration, CBD inhibited the virus’ ability to replicate.

Further investigation found that CBD had the same effect in two other types of cells and for three variants of SARS-CoV-2 in addition to the original strain.

CBD did not affect the ability of SARS-CoV-2 to enter the cell. Instead, CBD was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.

Like all viruses, SARS-CoV-2 affects the host cell by hijacking its gene expression machinery to produce more copies of itself and its viral proteins. This effect can be observed by tracking virus-induced changes in cellular RNAs. High concentrations of CBD almost completely eradicated the expression of viral RNAs.

READ MORE  Cannabis violence claims are ‘misinformed and reckless’

When it came to the other cannabinoids, CBD was found to be the only potentially potent agent. There was no or limited antiviral activity noted by the similar cannabinoids including THC, CBDA, CBDV, CBC or even CBG.

Marsha Rosner, PhD, professor and senior author of the study said it was a completely unexpected result, she commented: “CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm.’ Surprisingly, it directly inhibited viral replication in lung cells.

She added: “We just wanted to know if CBD would affect the immune system. No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

The researchers do caution that this is not possible with commercially available CBD. The CBD tested was high-purity and also medical grade.

However, Rosner cautioned:  “Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything. The commercially available CBD powder we looked at, which was off the shelf and something you could order online, was sometimes surprisingly of high purity but also of inconsistent quality. It is also hard to get into an oral solution that can be absorbed without the special, FDA-approved formulation.”

CBD and Covid studies

This is the second study to be released showing the potential for cannabinoids in Covid management and prevention.

A study by Oregon State University has revealed that the compounds cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), may have the ability to prevent the virus that causes Covid-19 from entering human cells.

READ MORE  Five professional athletes who use CBD

Researchers and scientists, led by Richard van Breedan, found that a pair of cannabinoid acids bind to the SARS-CoV-2 spike protein, blocking a step in the process the virus takes for infection.

Targeting compounds that block the virus-receptor interaction has been helpful for patients with other viral infections such as HIV-1 and hepatitis.

The researchers and scientists identified the two cannabinoid acids through a screening technique, developed previously in van Breeman’s laboratory. The team also screened different botanicals such as red clover, hops, wild yam and three types of liquorice.

Continue Reading

News

Partner of Irish politician “six years seizure free” faces charges over medical cannabis use

John Montaine uses medical cannabis to manage his epilepsy – and is said to be six years seizure free.

Published

on

Irish government medical cannabis
John Montaine, is the partner of Clare Sinn Fein TD Violet Ann Wynne.

The partner of a sitting Irish TD is contesting charges of cannabis possession, saying he uses it medicinally to manage his epilepsy.

John Montaine, who is the partner of Clare Sinn Fein TD Violet Ann Wynne, was charged with the alleged illegal possession of cannabis on February 11, 2021, at his family home, the Irish Independent reported.

Mr Montaine contests the charges and his partner Deputy Wynne has previously spoken publicly about how he uses cannabis medicinally to manage his epilepsy.

Speaking after the initial court hearing in November, Deputy Wynne said in March her partner would be “six years seizure free”.

She went on to say that it has improved his quality of life “100 per cent, without a doubt”.

“There was always some kind of issue – say John having a number of fits within the one month or losing teeth or suffering with severe migraine, but since John has been using the medicinal cannabis, he has had a better quality of life,” Deputy Wynne told the Independent.

She added: “It has also freed myself up. John would have been on disability allowance and I would have had to have been his carer but since using the medicinal cannabis, he doesn’t suffer from any of those issues any longer.”

Medical cannabis is legal in Ireland, but access to a prescription is limited.

Last year Ryan Gorman, a 26-year-old man, from Dublin, who also suffers from epilepsy, became the first patient to receive a cannabis-based medicine through the Medical Cannabis Access Programme.

Despite legislation being signed off in 2019, Ireland’s Health minister Stephen Donnelly only announced funding for it in January 2021, with the programme only becoming fully operational in November.

Four cannabis-based medicines are expected to be available through the MCAP, to people living with one of three qualifying conditions. These include intractable nausea and vomiting associated with chemotherapy, severe treatment-resistant epilepsy and spasticity associated with multiple sclerosis (MS). 

Mr Montaine’s solicitor appeared in Kilrush District Court on behalf of his client this week, where his case was adjourned until 15 March.

READ MORE  ‘It’s time to put medical cannabis back on the agenda’
Continue Reading

Trending